In 2012, the Canadian Scleroderma Multicenter Study Group’s comprehensive analysis of autoantibodies associated with 963 patients with SSc showed that anti-TRIM21 was detected in 20% of patients and was the second most common autoantibody in the patient cohort, except for anti-centromere antibodies (119). This evidence concerns the gene TRIM21 and systemic sclerosis.